Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer
- 1 September 1998
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 70 (3) , 392-397
- https://doi.org/10.1006/gyno.1998.5109
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Tumor chemosensitivity and chemoresistance assaysCancer, 1997
- Tumor chemosensitivity and chemoresistance assaysCancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Combination chemotherapy tested in a short‐term thymidine incorporation assay in primary cultures of ovarian adenocarcinomasThe International Journal of Cell Cloning, 1992
- Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assayThe Lancet, 1991
- Testing chemotherapeutic combinations in the human tumor colony—forming assayJournal of Surgical Oncology, 1988
- AnnouncementGynecologic Oncology, 1986
- Evolution and clinical application of a rapid chemosensitivity assayCancer, 1985
- The Power Function of the "Exact" Test for Comparing Two Binomial DistributionsJournal of the Royal Statistical Society Series C: Applied Statistics, 1978
- Primary Bioassay of Human Tumor Stem CellsScience, 1977